Form 4: Plus Therapeutics Director Acquires Shares and Warrants

Director Richard J. Hawkins reports acquisition of Plus Therapeutics common stock and warrants.

Summary

• On May 8, 2024, Richard J. Hawkins, a director of Plus Therapeutics, acquired 4,902 shares of common stock at a price of $2.04 per share.
• Following the transaction, Mr. Hawkins directly owns 4,903 shares of common stock.
• On the same day, Mr. Hawkins also acquired 9,804 warrants with an exercise price of $1.79.
• Half of the warrants (4,902) expire on May 8, 2029 (Series A), while the other half (4,902) expire one year after the registration statement covering the resale of underlying common stock becomes effective (Series B).
• Following the transaction, Mr. Hawkins directly owns 9,804 warrants.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The director's purchase could be seen as a positive signal, but it's a relatively small transaction.

Positives

• Director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, regarding their holdings of the company's securities.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Richard J. Hawkins, Plus Therapeutics, PSTV, Director, Common Stock, Warrants, Acquisition